These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An economic evaluation of "Health for All". Patel M Health Policy Plan; 1986 Mar; 1(1):37-47. PubMed ID: 10312155 [TBL] [Abstract][Full Text] [Related]
25. [Towards a new vaccine economy?]. Poirot P; Martin JF Sante; 1994; 4(3):183-7. PubMed ID: 7921683 [TBL] [Abstract][Full Text] [Related]
26. [Vaccines: producers in countries of the Southern hemisphere]. Bertrand JJ Med Trop (Mars); 2007 Aug; 67(4):347-50. PubMed ID: 17926792 [TBL] [Abstract][Full Text] [Related]
27. Children's vaccine initiative. World Health Forum; 1993; 14(2):202-3. PubMed ID: 8185773 [TBL] [Abstract][Full Text] [Related]
28. Global support for new vaccine implementation in middle-income countries. Kaddar M; Schmitt S; Makinen M; Milstien J Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496 [TBL] [Abstract][Full Text] [Related]
29. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
30. Availability of quality vaccines: policies of a non-government organization. Poore P Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421 [TBL] [Abstract][Full Text] [Related]
31. The imperative for stronger vaccine supply and logistics systems. Zaffran M; Vandelaer J; Kristensen D; Melgaard B; Yadav P; Antwi-Agyei KO; Lasher H Vaccine; 2013 Apr; 31 Suppl 2():B73-80. PubMed ID: 23598495 [TBL] [Abstract][Full Text] [Related]
32. Geneva-Seattle collaboration in support of developing country vaccine manufacturing. Stevenson MA Glob Public Health; 2018 Apr; 13(4):426-441. PubMed ID: 27760489 [TBL] [Abstract][Full Text] [Related]
33. Transferring manufacturing technology. Producing essential vaccines in Pakistan. Burney MI Int J Technol Assess Health Care; 1993; 9(3):397-406. PubMed ID: 8340204 [TBL] [Abstract][Full Text] [Related]
34. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Peny JM; Gleizes O; Covilard JP Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769 [TBL] [Abstract][Full Text] [Related]
35. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012. Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836 [TBL] [Abstract][Full Text] [Related]
37. Vaccines, inspiring innovation in health. Pagliusi S; Dennehy M; Kim H; Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241 [TBL] [Abstract][Full Text] [Related]
38. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all. Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479 [TBL] [Abstract][Full Text] [Related]
39. Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives. Cortes Mde L; Cardoso D; Fitzgerald J; DiFabio JL Biologicals; 2012 Jan; 40(1):3-14. PubMed ID: 22033155 [TBL] [Abstract][Full Text] [Related]
40. Sustainable vaccine manufacturing in low- and middle-Income countries. Hayman B; Kumar Suri R; Downham M Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]